Gold tier: mechanically validated evidence, with its primary source.
238 evidence items · page 6 / 10
76.3 %Among healthcare professionals in Sierra Leone surveyed from January to March 2022, 76.3% reported worries about unforeseen future effects of COVID-19 vaccines.
Sierra LeoneCOVID-19observed January to March 2022published 2022Vaccineseurope_pmcdocument of 12 observations
68.8 %Antibiotics were used in 68.8% of the articles on COVID-19 patients with sepsis or septic shock.
Sierra LeoneCOVID-19 · sepsis · septic shockpublished 2020Sepsis and septic shock in COVID-19: a scoping review of the research dataeurope_pmcdocument of 17 observationsDOI 10.21203/rs.3.rs-30474/v1
11.4 %The prevalence of chronic kidney disease (CKD) among adults in Freetown, Sierra Leone was 11.4%.
Sierra Leonemaladie rénale chroniqueobserved 2019–2021published 2023BMJ openeurope_pmcdocument of 6 observations
12 %Minority HIV-1 variants constituted 12% of sequenced samples in Sierra Leone.
Sierra LeoneVIH/sidapublished 2021Geneseurope_pmcdocument of 21 observationsDOI 10.3390/genes12091314
87.9 %The predominant HIV-1 subtype in Sierra Leone was CRF02_AG, accounting for 87.9% (95/108) of sequenced samples.
Sierra LeoneVIH/sidapublished 2021Geneseurope_pmcdocument of 21 observationsDOI 10.3390/genes12091314
16 %The likelihood of a positive HIV test was 16% higher in 2021 than in 2019 (prevalence ratio 1.16).
Sierra LeoneVIH/sidaobserved 2021published 2024AIDS and behavioreurope_pmcdocument of 7 observations
58,300 vaccine_doses58,300 MVA-BN vaccine doses were delivered to Sierra Leone for Mpox.
Sierra LeonempoxAfrica CDCdocument of 72 observations
15.3 %Among 275 newly diagnosed people living with HIV (PWH) enrolled in the Sierra Leone HIV Cohort Study in Freetown from March to September 2021, 15.3% had HIV/HBV coinfection.
Sierra LeoneHIV/HBV coinfectionobserved March to September 2021published 2022Journal of clinical medicineeurope_pmcdocument of 9 observations
74.7 %The proportion of drug-resistant TB cases that completed treatment decreased from 74.7% in the pre-COVID-19 period to 63.3% during the COVID-19 period.
Sierra Leonedrug-resistant TBobserved pre-COVID-19published 2025Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a nateurope_pmcdocument of 9 observations
24.3 %HIV test was positive in 925 out of 3808 clients tested, representing 24.3%, at Connaught Hospital in Sierra Leone from January to December 2017.
Sierra LeoneVIH/sidaobserved January to December 2017published 2019Low Partner Testing in High HIV Prevalence Setting in Freetown, Sierra Leone: A Retrospecteurope_pmcdocument of 5 observationsDOI 10.21203/rs.2.11135/v3
10 %Of the gram-negative bacteria, 10% were carbapenem-resistant Enterobacteriaceae.
Sierra Leonecarbapenem-resistant Enterobacteriaceaepublished 2022Therapeutic advances in infectious diseaseeurope_pmcdocument of 6 observations
60.1 %Among healthcare professionals in Sierra Leone surveyed from January to March 2022, 60.1% were classified as vaccine hesitant (above the 50th percentile of the VAX score).
Sierra LeoneCOVID-19observed January to March 2022published 2022Vaccineseurope_pmcdocument of 12 observations
6.8 %The estimated prevalence of sepsis among COVID-19 patients ranges from 6.8% to 100%.
Sierra LeoneCOVID-19 · sepsispublished 2020Sepsis and septic shock in COVID-19: a scoping review of the research dataeurope_pmcdocument of 17 observationsDOI 10.21203/rs.3.rs-30474/v1
273 per_100000Sierra Leone has a TB incidence rate of 273 per 100,000 population in 2023.
Sierra Leonetuberculoseobserved 2023published 2026PLOS global public healtheurope_pmcdocument of 6 observations
74 %The case fatality rate among patients with Ebola virus disease in Sierra Leone was 74%.
Sierra Leonemaladie à virus Ebolaobserved 2014published 2014The New England journal of medicineeurope_pmcdocument of 14 observations
63.3 %The proportion of drug-resistant TB cases that completed treatment was 63.3% during the COVID-19 period.
Sierra Leonedrug-resistant TBobserved during COVID-19published 2025Effect of the COVID-19 pandemic on drug-resistant tuberculosis treatment outcomes at a nateurope_pmcdocument of 9 observations
98.8 %Preoperative antibiotic use for caesarean section patients was 98.8% in 2023.
Sierra Leonesurgical site infectionsobserved 2023published 2023Tropical medicine and infectious diseaseeurope_pmcdocument of 5 observationsDOI 10.3390/tropicalmed8080385
478 casesIn Sierra Leone, invasive aspergillosis is estimated at 478 annual cases.
Sierra Leoneinvasive aspergillosispublished 2021Therapeutic advances in infectious diseaseeurope_pmcdocument of 9 observations
8.7 %Among 275 newly diagnosed people living with HIV (PWH) enrolled in the Sierra Leone HIV Cohort Study in Freetown from March to September 2021, 8.7% had HIV/TB coinfection.
Sierra LeoneHIV/TB coinfectionobserved March to September 2021published 2022Journal of clinical medicineeurope_pmcdocument of 9 observations
38 yearsThe median age of enrolled people with HIV in Freetown, Sierra Leone was 38 years.
Sierra LeoneVIH/sidaobserved April to June 2022published 2023Vaccineseurope_pmcdocument of 5 observationsDOI 10.3390/vaccines11111685
Benin, Liberia, and Sierra Leone launched mass malaria vaccination in children on 25 April 2024.
Bénin · Liberia · Sierra Leonepaludismeobserved 25 April 2024HAL · Unilimdocument of 84 observations
21.1 %The prevalence of dyslipidaemia among adults in Freetown, Sierra Leone was 21.1%.
Sierra Leonedyslipidemiaobserved 2019–2021published 2023BMJ openeurope_pmcdocument of 6 observations
8.3 %The prevalence of diabetes mellitus among adults in Freetown, Sierra Leone was 8.3%.
Sierra Leonediabète (non précisé)observed 2019–2021published 2023BMJ openeurope_pmcdocument of 6 observations
24.1 %Among 761 HIV-exposed infants (HEIs), 176 (24.1%) received a second virological test 12 weeks after cessation of breastfeeding.
Sierra LeoneVIH/sidapublished 2026PLOS global public healtheurope_pmcdocument of 6 observations
21.1 %The prevalence of dyslipidemia among adults in Freetown, Sierra Leone was 21.1%.
Sierra Leonedyslipidemiaobserved 2019–2021published 2023Burden of cardiometabolic risk factors and preclinical target organ damage among adults ineurope_pmcdocument of 8 observationsDOI 10.1101/2023.02.20.23286145
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.